Meeting
2018 ASCO Annual Meeting
Residual risk assessment with the Breast Cancer Index (BCI) for prediction of late distant recurrence (DR) in patients from the TransATAC study.
Authors
Ivana Sestak
Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom
Ivana Sestak , Yi Zhang , Dennis Sgroi , Catherine A. Schnabel , Jack M. Cuzick , Mitchell Dowsett
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 36, 2018 (suppl; abstr 529)
DOI
10.1200/JCO.2018.36.15_suppl.529
Abstract #
529
Poster Bd #
21
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer.
First Author: Ciara Marie Kelly
Poster
2013 ASCO Annual Meeting
Prediction of early and late distant recurrence in early-stage breast cancer with Breast Cancer Index.
First Author: Yi Zhang
Poster
2023 ASCO Annual Meeting
lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).
First Author: Charles Geyer
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden